A number of heterocycles bearing an arylpiperazinylalkyl side chain and structurally related to the previously described lead ET1 (4-amino-6-methyl-2-[3-(4-p-tolylpiperazin-1-yl)propyl]-5-vinylpyridazin-3 (2H)-one) was synthesized and tested for their antinociceptive activity in Writhing Test. Many compounds, tested at doses of 20–40 mg/kg po were able to reduce the number of abdominal constrictions by more than 47% and, in same cases, the potency is comparable to lead ET1 as for 5e, 24a, 27b and 27c. The analgesia induced by the active compounds was completely prevented by pretreatment with a2-antagonist yohimbine, confirming the involvement of the adrenergic system in the mechanism of action for these new compounds.
Synthesis of five and six-membered heterocycles bearing an arylpiperazinylalkyl side chain as orally active antinociceptive agents / Claudia Vergelli; Giovanna Ciciani; Agostino Cilibrizzi; Letizia Crocetti; Lorenzo Di Cesare Mannelli; Carla Ghelardini; Gabriella Guerrini; Antonella Iacovone; Maria Paola Giovannoni. - In: BIOORGANIC & MEDICINAL CHEMISTRY. - ISSN 0968-0896. - ELETTRONICO. - 23:(2015), pp. 6237-6245.
Synthesis of five and six-membered heterocycles bearing an arylpiperazinylalkyl side chain as orally active antinociceptive agents
VERGELLI, CLAUDIA;CICIANI, GIOVANNA;CROCETTI, LETIZIA;DI CESARE MANNELLI, LORENZO;GHELARDINI, CARLA;GUERRINI, GABRIELLA;IACOVONE, ANTONELLA;GIOVANNONI, MARIA PAOLA
2015
Abstract
A number of heterocycles bearing an arylpiperazinylalkyl side chain and structurally related to the previously described lead ET1 (4-amino-6-methyl-2-[3-(4-p-tolylpiperazin-1-yl)propyl]-5-vinylpyridazin-3 (2H)-one) was synthesized and tested for their antinociceptive activity in Writhing Test. Many compounds, tested at doses of 20–40 mg/kg po were able to reduce the number of abdominal constrictions by more than 47% and, in same cases, the potency is comparable to lead ET1 as for 5e, 24a, 27b and 27c. The analgesia induced by the active compounds was completely prevented by pretreatment with a2-antagonist yohimbine, confirming the involvement of the adrenergic system in the mechanism of action for these new compounds.File | Dimensione | Formato | |
---|---|---|---|
Bioorg Vergelli 2015.pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Tutti i diritti riservati
Dimensione
1.15 MB
Formato
Adobe PDF
|
1.15 MB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.